Phaseline

Targets › GYRB

GYRB: drug programs, companies and trials

8 programs from 8 companies in 9 trials: 4 Phase 2, 3 Phase 4, 1 Phase 3, 1 Phase 1; Infectious disease, Ophthalmology, Respiratory; next expected readout Nov 2026.

Open in Phaseline: the race on GYRB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kazakh Eye Research InstitutePicloxidine
DNA gyrase inhibitor (broad-spectrum antimicrobial agent)
GYRBPhase 4Neonatal DacryocystitisNov 2026
Assiut UniversityLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, GYRBPhase 4Bronchiectasis With Acute ExacerbationFeb 2027
Mahidol UniversityLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, GYRBPhase 4BacteremiaDec 2027
Laboratorios Sophia S.A de C.V.Moxifloxacin (PRO-232)
Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor
GYRB, NR3C1Phase 3Cataract Extraction–
McGill University Health Centre/Research Institute of the McGill University Health CentreLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRB, RNAPPhase 2Tuberculosis Infection, LatentApr 2027
Copenhagen Respiratory ResearchLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, GYRBPhase 2Community-acquired Pneumonia; Community Acquired Pneumonia (CAP)Sep 2028
Al-Mustafa University CollegeCiprofloxacin
Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRBPhase 2Cutaneous Leishmaniasis–
National University Hospital, SingaporeCiprofloxacin
Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, GYRBPhase 1Metastatic Pancreatic Ductal AdenocarcinomaFeb 2027

Conditions

Neonatal Dacryocystitis (1) Tuberculosis Infection, Latent (1) Bronchiectasis With Acute Exacerbation (1) Cataract Extraction (1) Cutaneous Leishmaniasis (1) Community-acquired Pneumonia (1) Community Acquired Pneumonia (CAP) (1) Metastatic Pancreatic Ductal Adenocarcinoma (1) Bacteremia (1)

Modalities

small molecule (8)

Companies

Kazakh Eye Research Institute (1) McGill University Health Centre/Research Institute of the McGill University Health Centre (1) Assiut University (1) Laboratorios Sophia S.A de C.V. (1) Al-Mustafa University College (1) Copenhagen Respiratory Research (1) National University Hospital, Singapore (1) Mahidol University (1)

Related targets

GYRA (4) RNAP (1) NR3C1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.